-Wave provides evidence-based menstrual pain and symptom treatment
-Wave products are naproxen-based; NSAIDs are first-line treatment
-There is no current NSAID product on the market targeted at period pain
-Wave's unique timing and dosing regimens have a patent pending
-Wave products lend themselves to subscription services
-Wave's GTM strategy includes a launch on amazon and DTC
-Wave's gross margins are estimated around 75 - 85%